Click here to go to the previous page
Around They Go, and Where They Stop, Only the Inhibitors Know
Program Code:
BTB050
Date:
Tuesday, May 8, 2007
Time:
9:15 AM to 10:45 AM
SPEAKER
(S):
David Mathews, Senior Director, Oncology, Exelixis, Inc.
Spiro Rombotis, President & Chief Executive Officer, Cyclacel Pharmaceuticals, Inc.
Neil W. Gibson, PhD, Chief Scientific Officer, OSI Pharmaceuticals, Inc.
John Lyons, Vice President Translational Biology, Astex Therapeutics Limited
Carolyn Buser-Doepner, Associate Director Clinical Research, Merck Research Laboratories
Description
Cell cycle inhibitors may represent an important change in the field of drug discovery, and ultimately in the treatment of cancer and other diseases. Recent insights in academia and industry, bolstered by advances in genomics, have suggested therapeutic approaches that target new aspects of cancer cell cycles; specifically, the interactions and pathways altered in these cells.
Objectives:
Outline advances that are now making it possible to selectively inhibit the cell cycle to treat cancer and other serious disorders.
Highlight clinical and development progress of some of the most advanced compounds resulting from this research.
Identify the most promising opportunities as well as bottlenecks in this area of research.